Thomas Riley III, MD, MS - Penn State Cancer Institute
Researcher Profile
Thomas Riley III, MD, MS
Professor, Department of Medicine
Division of Gastroenterology and Hepatology
Division of Gastroenterology and Hepatology
Disease Teams:
Cancer Institute, Liver, Pancreas and Foregut Cancer Team
Research Interests
- Therapeutics
- Liver
- Liver Diseases
- Liver Transplantation
- Chronic Disease
- Antiviral Agents
- Hepatitis C
- Chronic Hepatitis C
- Hepacivirus
- Fibrosis
- Medicare
- Biopsy
Recent Publications
2022
Tran, L, Jung, J, Feldman, R & Riley, T 2022, 'Disparities in the quality of care for chronic hepatitis C among Medicare beneficiaries', PloS one, vol. 17, no. 3 March, e0263913. https://doi.org/10.1371/journal.pone.0263913
Stine, JG, Schreibman, IR, Faust, AJ, Dahmus, J, Stern, B, Soriano, C, Rivas, G, Hummer, B, Kimball, SR, Geyer, NR, Chinchilli, VM, Loomba, R, Schmitz, K, Sciamanna, C, Strine, C, Wentzel, R, Marlin, S, Sica, C, Vesek, J, Eyster, E, Sinoway, L, Bentz, K, Handley, N, Hershey Fell, B, Mottilla, S, Christ, C, George, S, Novchich, T, Beyer, M, Clarke, K, Myers, T, Glading-Steinruck, M, Krok, K, Ma, T, Riley, T, Thompson, E, Tressler, H, Broach, J, Doan, T, Patrick, S, Reed, S, Hamilton, C, Slavoski, K & Tregea, D 2022, 'NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH', Hepatology, vol. 76, no. 1, pp. 172-185. https://doi.org/10.1002/hep.32274
2021
Tran, L, Feldman, R, Riley, T & Jung, J 2021, 'Association of the Extension for Community Healthcare Outcomes Project with Use of Direct-Acting Antiviral Treatment among US Adults with Hepatitis C', JAMA network open, vol. 4, no. 7, e2115523. https://doi.org/10.1001/jamanetworkopen.2021.15523
Du, P, Wang, X, Kong, L, Riley, T & Jung, J 2021, 'Changing Urban–Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014–2017', American Journal of Preventive Medicine, vol. 60, no. 2, pp. 285-293. https://doi.org/10.1016/j.amepre.2020.08.031
Kadry, Z, Schaefer, E, Krok, K, Faust, A, Stine, JG, Schreibman, IR, Bezinover, D & Riley, TR 2021, 'Excellent outcomes with liver transplantation in hepatopulmonary syndrome across pre-transplant PaO2 spectrum', JHEP Reports, vol. 3, no. 5, 100351. https://doi.org/10.1016/j.jhepr.2021.100351
Roy, J, Kang, M, Stern, B, Riley, T & Schreibman, I 2021, 'Lactulose-induced pneumatosis intestinalis following colonoscopy: a case report', Clinical Journal of Gastroenterology, vol. 14, no. 4, pp. 1152-1156. https://doi.org/10.1007/s12328-021-01392-9
Du, P, Jung, J, Kalidindi, Y, Farrow, K, Riley, T & Whitener, C 2022, 'Low utilization of direct-acting antiviral agents in a large national cohort of HIV and HCV coinfected Medicare patients in the United States: Implications for HCV elimination', Journal of Public Health Management and Practice, vol. 28, no. 2, pp. 130-134. https://doi.org/10.1097/PHH.0000000000001147
Noverati, N, Federici, E & Riley, TR 2021, 'Post-transfusion hemoglobin response in patients with cirrhosis: Can we expect a 1 g/dL rise per unit transfused?', Transfusion, vol. 61, no. 3, pp. 708-712. https://doi.org/10.1111/trf.16238
Kadry, Z, Stine, JG, Dohi, T, Jain, A, Robyak, KL, Kwon, O, Hamilton, CJ, Janicki, P, Riley, TR, Butt, F, Krok, K, Schreibman, IR, Bezinover, D, Ghahramani, N, Campos, S & Hollenbeak, CS 2021, 'Renal Protective Effect of Everolimus in Liver Transplantation: A Prospective Randomized Open-Label Trial', Transplantation Direct, vol. 7, no. 7, pp. E709. https://doi.org/10.1097/TXD.0000000000001159
2020
Jung, J, Feldman, R, Kalidindi, Y & Riley, T 2020, 'Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries', JAMA network open, vol. 3, no. 6, pp. e208081. https://doi.org/10.1001/jamanetworkopen.2020.8081
Kalidindi, Y, Jung, J, Feldman, R & Riley, T 2020, 'Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C', JAMA network open, vol. 3, no. 7, pp. e2011055. https://doi.org/10.1001/jamanetworkopen.2020.11055
Jung, J, Du, P, Feldman, R & Riley, T 2020, 'Discontinuation of new hepatitis C drugs among Medicare patients', American Journal of Managed Care, vol. 26, no. 2, pp. 84-88. https://doi.org/10.37765/ajmc.2020.42397
Jain, A, Riley, TR, Krok, KL, Schreibman, I, Karamchandani, DM, Liao, X, Tian, Y, Dohi, T & Kadry, Z 2020, 'Incidence of post-liver transplant hepatic dysfunction after sustained virologic response following direct-acting anti-hepatitis c therapy', Experimental and Clinical Transplantation, vol. 18, no. 3, pp. 345-352. https://doi.org/10.6002/ect.2018.0127
2019
Loloi, J, Patel, A, McDevitt, P, Bruno, MA & Riley, T 2019, 'How Strongly Do Physical Examination Estimates and Ultrasonographic Measurements of Liver Size Correlate? A Prospective Study', American Journal of Medicine, vol. 132, no. 1, pp. 103-108. https://doi.org/10.1016/j.amjmed.2018.09.012
Jain, A, Miller, D, Schreibman, I, Riley, TR, Krok, KL, Dohi, T, Sharma, R & Kadry, Z 2019, 'Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?', Hepatology International, vol. 13, no. 2, pp. 190-198. https://doi.org/10.1007/s12072-019-09930-x
Jung, J, Du, P, Feldman, R, Kong, L & Riley, T 2019, 'Racial/ethnic and socioeconomic disparities in use of direct-acting antivirals among Medicare beneficiaries with chronic hepatitis C, 2014-2016', Journal of Managed Care and Specialty Pharmacy, vol. 25, no. 11, pp. 1236-1242. https://doi.org/10.18553/jmcp.2019.25.11.1236